IRLAB Therapeutics AB (publ)

IRLAB-A · Nasdaq Stockholm · Healthcare

1.86SEK +1.6%last day

Price as of 2 October 2026

The price over the past year, with dividends: −36.4%

Performance

1 month

+7.8%

1 year

−36.4%

3 years, per year

−36.3%

5 years, per year

−47.2%

Largest fall, 3 years

−95.4%

Below the peak now

−98.2%

Volatility, 1 year

51.1%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.6

Dividend yield

0.0%

Return on equity

−55.4%

Net margin

−67.9%

Market value

16 m USD

Quality, value and trend

Where IRLAB Therapeutics stands against every Nordic stock today. 100 is best.

Quality31

Profitability and a sound balance sheet over time. Better than 31% of Nordic stocks.

Value30

The price measured against earnings, assets and cash flow. Better than 30% of Nordic stocks.

Trend68

The price development over the past year. Better than 68% of Nordic stocks.

Combined34

Quality, value and trend together. Better than 34% of Nordic stocks.

About IRLAB Therapeutics

IRLAB Therapeutics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 31 employees.

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson's disease, and in a Phase IIA clinical trial for dementia in Parkinson's disease; and IRL757, which is in a Phase I clinical trial for the treatment of apathy in Parkinson's and other neurolog…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis